5 employees
NeuroSigma develops and commercializes trigeminal nerve stimulation (TNS) for a variety of neurologic and psychiatric disorders.
2008
$5M
from 1 investors over 1 rounds
NeuroSigma raised $5M on December 8, 2021
Investors: KT